Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Endocrine and neuroendocrine tumours

4624 - Integrative DNA methylome and miRNA transcriptome analysis for new biomarker discovery in Entero-Pancreatic Neuroendocrine Tumours (EP-NETS)


11 Sep 2017


Endocrine and neuroendocrine tumours


Translational Research;  Neuroendocrine Tumours


Jorge Barriuso


Annals of Oncology (2017) 28 (suppl_5): v142-v157. 10.1093/annonc/mdx368


J. Barriuso1, A. Lamarca1, V. Heredia2, L. Guerra-Pastrian3, C. Alvarez-Escola4, J. Castell5, A. Custodio6, M. Miguel2, M. Mendiola2, J. Feliu7

Author affiliations

  • 1 Medical Oncology, The Christie NHS Foundation Trust, M20 4BX - Manchester/GB
  • 2 Translational Oncology, IdIPAZ – Hospital Universitario La Paz, Madrid/ES
  • 3 Pathology, IdIPAZ – Hospital Universitario La Paz, Madrid/ES
  • 4 Endocrinology, IdIPAZ – Hospital Universitario La Paz, Madrid/ES
  • 5 Surgical Oncology, IdIPAZ – Hospital Universitario La Paz, Madrid/ES
  • 6 Medical Oncology, IdIPAZ-Hospital Universitario la Paz, 28046 - Madrid/ES
  • 7 Medical Oncology, IdIPAZ – Hospital Universitario La Paz, Madrid/ES


Abstract 4624


Several attempts to improve the knowledge about the molecular biology of EP-NETS. However, the majority of these studies rely on alterations or pattern descriptions rather than integrative analysis of the findings derived from different platforms. We aim to identify new potential biomarkers integrating the differential expression of miRNAs and DNA methylated regions.


From a series of 115 EP-NETS formalin-fixed and paraffin embedded samples, we selected 8 cases of small intestine (SI) NETS and 8 pancreatic (P) NETS based on relapse (yes vs no) trying to identify the most phenotypically different cases within these groups in our series. DNA and RNA were extracted. The methylome EPIC array was used to determine differentially methylated regions (DMRs) and a transcriptomic array was used to analyse miRNA expression. Quality check (QC) of data was ran prior to analysis. False discovery rate (FDR) was applied to correct for multiple comparisons. Chromosomal regions with differentially expressed miRNAs and DMRs were plotted to perform an integrative analysis.


Sample-wise and chip-wise QC were performed. DMRs were analyzed comparing patients with or without relapse (R) in SI-NETS and PNETS. The most significant differentially methylated regions for R vs non-R in PNETS were found in chromosome (chr) 2, and in chr 1 and 2 for SI-NETS. A gene set analysis of the DMRs was performed using a FDR < 0.1. Gene sets commonly represented in SI-NETS and PNETS are within CD8 TCR pathway and endothelin pathway. None of the miRNAs maintain significance using a FDR


It is feasible to integrate the analysis of DMRs and miRNAs in EP-NETS. Certain areas of chr1 and 2 concentrated regions with different epigenetic regulation when compare R vs non-R. Validation of the findings is ongoing.

Clinical trial identification

Legal entity responsible for the study

IdIPAZ - Hospital Universitario La Paz


Fundación Eugenio Rodriguez Pascual Fundación Eugenio Rodríguez Pascual; Sociedad Española de Oncología Medica


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.